Stocktoria
Torrent Pharmaceuticals Limited TORNTPHARM.NS
Torrent Pharmaceuticals Limited (TORNTPHARM.NS) earns a Piotroski F-score of 4/9 (mixed financial health). It pays a dividend yielding 0.68% (safety: moderate). FY2026 revenue was ₹137.5B at a 15.7% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
Forward estimates · earnings calendar →
Consensus analyst estimates and scheduled dates — forward-looking, may change.
How it ranks in Healthcare · percentile among 80 companies
Percentile vs other Healthcare companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 4/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
About Torrent Pharmaceuticals Limited
Torrent Pharmaceuticals Limited engages in the research, development, manufacturing, marketing, and distribution of branded and generic pharmaceutical formulations in India, the United States, Brazil, Germany, Malta, and internationally. The company offers products in various therapeutic areas, including anti-diabetic, anti-microbial, cardiovascular, CNS, urology, gynecology, oncology, gastro-intestinal, nephrology, neuro-psychiatric, dermatology, pulmonology, pediatric treatments, nutritional, pain management, anti-infective, and miscellaneous, as well as vitamins, minerals, and nutrients. It also provides contract manufacturing services. The company offers its products under Tedibar, Shelcal, Unienzyme, ProZuca, and Ahaglow brands. The company was formerly known as Trinity Laboratories and changed its name to Torrent Pharmaceuticals Limited in 1971. The company was founded in 1959 and is based in Ahmedabad, India. Torrent Pharmaceuticals Limited is a subsidiary of Torrent Investments Private Limited.
FAQ
Is TORNTPHARM.NS financially healthy?
Torrent Pharmaceuticals Limited's Piotroski F-score is 4/9 (8–9 is excellent, 0–3 weak).
Does TORNTPHARM.NS pay a dividend, and is it safe?
Yes. Torrent Pharmaceuticals Limited pays a dividend yielding about 0.68% with a 59.6% payout ratio, rated “moderate” for safety.
How profitable is TORNTPHARM.NS?
In FY2026, Torrent Pharmaceuticals Limited had a net margin of 15.7% and a return on equity of 25.8%.
What is TORNTPHARM.NS's P/E ratio?
Torrent Pharmaceuticals Limited's trailing price-to-earnings (P/E) ratio is about 88.0×, based on its latest annual earnings.
What is the analyst price target for TORNTPHARM.NS?
The average Wall-Street price target for Torrent Pharmaceuticals Limited is ₹4,912.38, about 1.9% below the recent price, from 29 analysts (consensus: buy).
Is TORNTPHARM.NS a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on Torrent Pharmaceuticals Limited: a Piotroski F-score of 4/9, a P/E of about 88.0×, a dividend yield of 0.68%. Weigh these quality and valuation signals against your own goals.
Computed from company filings · IN · as of 2026-03-31. Figures in INR. Facts plus Stocktoria's own computed scores — not investment advice.